Available Clinical Trials

Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.

To inquire about participation in a clinical trial, please contact us at (804) 893-8717.

Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.

Search Clinical Trials

Select Category       or   
Displaying All Clinical Trials (21 - 30 of 44)
J2J-MC-JZLH (EMBER-4)

A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant …

SWOG LUNG-MAP

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

NRG-GI008

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

NRG-BN011

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

NRG-BR002-Closed to Accural

Testing whether treating breast cancer metastases with surgery or high-dose radiation improves survival

NRG-CC011

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIAL

NRG-GI008

Using cancer cells in the blood (ctDNA) to determine the type of chemotherapy that will benefit patients who have had …

NRG-GU008

Testing the addition of the drug apalutamide to the usual hormone therapy and radiation therapy after surgery for prostate cancer

NSABP B-64

EXActDNA-003 /​ NSABP B-64:Study of Molecular Residual Disease Detection in Breast Cancer (MRD)

NSABP FB-12

An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel …